• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by HilleVax Inc.

    7/24/25 5:30:59 PM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $HLVX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    HilleVax, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    43157M102

    (CUSIP Number)


    07/17/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    43157M102


    1Names of Reporting Persons

    EcoR1 Capital, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,892,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,892,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,892,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.8 %
    12Type of Reporting Person (See Instructions)

    IA, OO

    Comment for Type of Reporting Person:  Percentage calculated based on 50,141,064 shares of Common Stock outstanding on May 5, 2025, as reported in the Form 10-Q filed by the Issuer for the quarter ended March 31, 2025.


    SCHEDULE 13G

    CUSIP No.
    43157M102


    1Names of Reporting Persons

    Oleg Nodelman
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,892,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,892,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,892,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.8 %
    12Type of Reporting Person (See Instructions)

    HC, IN

    Comment for Type of Reporting Person:  Percentage calculated based on 50,141,064 shares of Common Stock outstanding on May 5, 2025, as reported in the Form 10-Q filed by the Issuer for the quarter ended March 31, 2025.


    SCHEDULE 13G

    CUSIP No.
    43157M102


    1Names of Reporting Persons

    EcoR1 Capital Fund Qualified, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,709,498.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,709,498.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,709,498.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.4 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  Percentage calculated based on 50,141,064 shares of Common Stock outstanding on May 5, 2025, as reported in the Form 10-Q filed by the Issuer for the quarter ended March 31, 2025.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    HilleVax, Inc.
    (b)Address of issuer's principal executive offices:

    321 Harrison Avenue, Boston, MA 02118
    Item 2. 
    (a)Name of person filing:

    EcoR1 Capital, LLC, a Delaware limited liability company ("EcoR1") EcoR1 Capital Fund Qualified, L.P., a Delaware limited partnership ("Qualified Fund") Oleg Nodelman Qualified Fund is filing this statement jointly with the other reporting persons, but not as a member of a group, and it expressly disclaims membership in a group. In addition, the filing of this Schedule 13G on behalf of Qualified Fund should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any securities covered by this Schedule 13G. Each reporting person also disclaims beneficial ownership of the securities reported herein except to the extent of that person's pecuniary interest therein.
    (b)Address or principal business office or, if none, residence:

    357 Tehama Street #3 San Francisco, CA 94103
    (c)Citizenship:

    See Item 4 of the cover sheet for each reporting person.
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    43157M102
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    EcoR1: 2,892,000 Oleg Nodelman: 2,892,000 Qualified Fund: 2,709,498
    (b)Percent of class:

    EcoR1: 5.8% Oleg Nodelman: 5.8% Qualified Fund: 5.4%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    EcoR1: 0 Oleg Nodelman: 0 Qualified Fund: 0

     (ii) Shared power to vote or to direct the vote:

    EcoR1: 2,892,000 Oleg Nodelman: 2,892,000 Qualified Fund: 2,709,498

     (iii) Sole power to dispose or to direct the disposition of:

    EcoR1: 0 Oleg Nodelman: 0 Qualified Fund: 0

     (iv) Shared power to dispose or to direct the disposition of:

    EcoR1: 2,892,000 Oleg Nodelman: 2,892,000 Qualified Fund: 2,709,498

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    EcoR1 is the general partner and investment adviser of investment funds, including Qualified Fund. Mr. Nodelman is the control person of EcoR1.
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    EcoR1 Capital, LLC
     
    Signature:/s/ Oleg Nodelman
    Name/Title:Manager
    Date:07/24/2025
     
    Oleg Nodelman
     
    Signature:/s/ Oleg Nodelman
    Name/Title:Reporting person
    Date:07/24/2025
     
    EcoR1 Capital Fund Qualified, L.P.
     
    Signature:/s/ Oleg Nodelman
    Name/Title:Manager of the General Partner, EcoR1 Capital, LLC
    Date:07/24/2025
    Exhibit Information

    EXHIBIT 99.1 - AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G

    Get the next $HLVX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HLVX

    DatePrice TargetRatingAnalyst
    7/9/2024$28.00 → $2.00Outperform → Market Perform
    Leerink Partners
    7/9/2024$34.00 → $3.00Buy → Hold
    Stifel
    7/9/2024$28.00 → $2.00Buy → Neutral
    H.C. Wainwright
    7/8/2024Buy → Neutral
    Guggenheim
    7/8/2024$24.00 → $5.00Overweight → Neutral
    JP Morgan
    12/13/2023$28.00Buy
    H.C. Wainwright
    More analyst ratings

    $HLVX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Heron Patrick J was granted 17,199 shares (SEC Form 4)

    4 - HilleVax, Inc. (0001888012) (Issuer)

    6/25/25 5:07:01 PM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Kohli Aditya was granted 17,199 shares, increasing direct ownership by 3% to 698,171 units (SEC Form 4)

    4 - HilleVax, Inc. (0001888012) (Issuer)

    6/25/25 4:55:55 PM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Chu Shelley was granted 17,199 shares (SEC Form 4)

    4 - HilleVax, Inc. (0001888012) (Issuer)

    6/25/25 4:25:38 PM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $HLVX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HilleVax downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded HilleVax from Outperform to Market Perform and set a new price target of $2.00 from $28.00 previously

    7/9/24 9:48:14 AM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    HilleVax downgraded by Stifel with a new price target

    Stifel downgraded HilleVax from Buy to Hold and set a new price target of $3.00 from $34.00 previously

    7/9/24 7:46:22 AM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    HilleVax downgraded by H.C. Wainwright with a new price target

    H.C. Wainwright downgraded HilleVax from Buy to Neutral and set a new price target of $2.00 from $28.00 previously

    7/9/24 7:46:01 AM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $HLVX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    HilleVax Reports Second Quarter 2025 Financial Results

    BOSTON, Aug. 06, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended June 30, 2025. Second Quarter Financial Results As of June 30, 2025 and December 31, 2024, the company had cash, cash equivalents and marketable securities totaling $159.5 million and $171.4 million, respectively. Research and development expenses were $3.3 million, compared to $52.6 million for the six months ended June 30, 2025 and 2024. The decrease was primarily due to lower clinical development costs. General and administrative expenses were $11.3 million,

    8/6/25 4:05:00 PM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right

    BOSTON and EMERYVILLE, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX) and XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) announced today they have entered into a definitive merger agreement (the "Merger Agreement"), whereby XOMA Royalty will acquire all of the issued and outstanding common shares of HilleVax.   Under the terms of the Merger Agreement, HilleVax stockholders will receive $1.95 in cash per share of HilleVax common stock at the closing of the merger, plus one non-transferable contingent value right ("CVR"), which represents the right to receive potential payments following the closing of a pro rata portion of:

    8/4/25 7:00:00 AM ET
    $HLVX
    $XOMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    HilleVax Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress

    $159.5 million of cash, cash equivalents and marketable securities as of March 31, 2025 The company is exploring the potential for continued development of its norovirus vaccine candidates inadults as well as business development related activities and other strategic alternatives BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended March 31, 2025. First Quarter Financial Results As of March 31, 2025 and December 31, 2024, the company had cash, cash equivalents and marketable securities totaling $159.5 million and

    5/8/25 7:00:30 AM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $HLVX
    SEC Filings

    View All

    $HLVX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form SC 14D9 filed by HilleVax Inc.

    SC 14D9 - HilleVax, Inc. (0001888012) (Subject)

    8/18/25 8:59:03 AM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC TO-T filed by HilleVax Inc.

    SC TO-T - HilleVax, Inc. (0001888012) (Subject)

    8/18/25 8:23:43 AM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC14D9C filed by HilleVax Inc.

    SC14D9C - HilleVax, Inc. (0001888012) (Subject)

    8/6/25 4:22:35 PM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Frazier Life Sciences X, L.P. bought $128,325 worth of shares (8,850 units at $14.50) (SEC Form 4)

    4 - HilleVax, Inc. (0001888012) (Issuer)

    4/8/24 4:22:13 PM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Mcloughlin Sean bought $21,225 worth of shares (1,250 units at $16.98) (SEC Form 4)

    4 - HilleVax, Inc. (0001888012) (Issuer)

    4/1/24 4:08:42 PM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $HLVX
    Leadership Updates

    Live Leadership Updates

    View All

    Frazier Life Sciences Appoints Aditya Kohli to Partner

    Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointment of Aditya Kohli, Ph.D., to Partner. Since joining FLS in 2016, Dr. Kohli has played a foundational role in company creation, co-founding six life sciences companies, including HilleVax (NASDAQ:HLVX, IPO in 2022)), Phathom Pharmaceuticals (NASDAQ:PHAT, IPO in 2019)), and Scout Bio (acquired by Ceva Santé Animale). He previously acted as Chief Business Officer at Phathom, Chief Operating Officer at HilleVax, and served on the Board of Scout Bio. He currently serves on the Board of HilleVax. "Aditya has been a valued member of the FLS team, and we are thrilled to se

    4/17/25 8:00:00 AM ET
    $HLVX
    $PHAT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    HilleVax Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress

    Topline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024 $272.7 million of cash, cash equivalents and marketable securities as of March 31, 2024 BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended March 31, 2024, highlighted recent progress and outlined key upcoming milestones for HIL-214, the company's investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis. "We are excited to remain on track to r

    5/9/24 4:05:00 PM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    HilleVax Announces Executive Management Appointment of Sean McLoughlin as Chief Operating Officer

    BOSTON, Jan. 18, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the appointment of Sean McLoughlin as Chief Operating Officer. As part of a planned transition in connection with Mr. McLoughlin's appointment, Co-founder and current Chief Operating Officer Dr. Aditya Kohli will remain a full-time executive with the company as Chief Business Officer, where he will be responsible for business development and corporate strategy.  Mr. McLoughlin has three decades of commercial and operational experience in vaccines, most recently as the Global Vaccine Commercialization Le

    1/18/24 7:00:00 AM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $HLVX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by HilleVax Inc.

    SC 13G/A - HilleVax, Inc. (0001888012) (Subject)

    11/14/24 9:36:33 AM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by HilleVax Inc.

    SC 13G/A - HilleVax, Inc. (0001888012) (Subject)

    11/14/24 9:00:08 AM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by HilleVax Inc.

    SC 13G - HilleVax, Inc. (0001888012) (Subject)

    7/22/24 9:02:05 PM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $HLVX
    Financials

    Live finance-specific insights

    View All

    HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right

    BOSTON and EMERYVILLE, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX) and XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) announced today they have entered into a definitive merger agreement (the "Merger Agreement"), whereby XOMA Royalty will acquire all of the issued and outstanding common shares of HilleVax.   Under the terms of the Merger Agreement, HilleVax stockholders will receive $1.95 in cash per share of HilleVax common stock at the closing of the merger, plus one non-transferable contingent value right ("CVR"), which represents the right to receive potential payments following the closing of a pro rata portion of:

    8/4/25 7:00:00 AM ET
    $HLVX
    $XOMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    HilleVax to Participate in J.P. Morgan Biotech – 2022 Conference Call Series

    BOSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will participate in the J.P Morgan Biotech – 2022 Conference Call Series. HIL-214, HilleVax's investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and the related ongoing Phase 2b study NEST-IN1 will be topics of discussion. Fireside chat details:Date:  Tuesday, September 6, 2022Time:  1:00 – 2:00 p.m. Eastern Daylight Time (EDT)Moderator:  Eric Joseph, Ph.D.HilleVax Participant:  Robert Hershberg, M.D., Ph.D.,

    9/1/22 5:18:14 PM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care